Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, May 31, 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF),the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharma...
NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development
LUND, Sweden and SEOUL, South Korea, May 21, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced positive topline results after data base lock in the phase I single...
NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases
LUND, Sweden, April 18, 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by the United States FDA Office of Orphan Products Development for its project KL133...
NeuroVive Board Chair Resigns, New Chair Elected
LUND, Sweden, Nov. 7, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces thatGregory Batcheller resigned as Chair of the NeuroVive Pharmaceutical AB Board effective midnightNovember 6, 2017. He had served as the Executive Chair of NeuroVive for the p...
NeuroVive Conducts a Directed New Share Issue of SEK 5.3 Million
LUND, Sweden, Nov. 3, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), a leading company in mitochondrial medicine, announced today that the company is conducting a directed new issue of shares, which is expected to add close toSEK 5.3 million to NeuroVive...
